Advanced non-small cell lung cancer harboring the KRAS G12C mutation research hub

KontRASt-02: A randomized, controlled, open label, phase III study evaluating the efficacy and safety of JDQ443 versus docetaxel in previously treated subjects with locally advanced or metastatic KRAS G12C mutant non-small cell lung cancer.

This clinical trial compares a new targeted drug called JDQ443 with standard chemotherapy (docetaxel). It is for adults with advanced non-small cell lung cancer that carries a specific genetic change called KRAS G12C. Researchers want to find out which treatment keeps cancer from growing for longer.